In 2023, Zhou et al. reported the clinical pharmacology profile of AMG119, the pioneering CAR-T cell therapy targeting DLL3, in individuals with relapsed/refractory (R/R) SCLC and obtained encouraging cellular kinetics data [77], bringing hope for the drug to market. Here, DLL3 is linked to small cell lung carcinoma.